ProfileGDS5678 / 1454989_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 69% 75% 74% 73% 74% 76% 76% 74% 71% 73% 78% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8114374
GSM967853U87-EV human glioblastoma xenograft - Control 24.7923774
GSM967854U87-EV human glioblastoma xenograft - Control 34.2874769
GSM967855U87-EV human glioblastoma xenograft - Control 45.0781575
GSM967856U87-EV human glioblastoma xenograft - Control 54.8367774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6439273
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7956374
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0495676
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1288276
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8273474
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4818871
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7662573
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4077778
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1195576